Seronil may be available in the countries listed below.
Fluoxetine hydrochloride (a derivative of Fluoxetine) is reported as an ingredient of Seronil in the following countries:
International Drug Name Search
Propofol Kabi may be available in the countries listed below.
Propofol is reported as an ingredient of Propofol Kabi in the following countries:
International Drug Name Search
Elmifarma may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Levamisole hydrochloride (a derivative of Levamisole) is reported as an ingredient of Elmifarma in the following countries:
International Drug Name Search
Pen-A may be available in the countries listed below.
Ampicillin sodium salt (a derivative of Ampicillin) is reported as an ingredient of Pen-A in the following countries:
Ampicillin trihydrate (a derivative of Ampicillin) is reported as an ingredient of Pen-A in the following countries:
International Drug Name Search
Neostigmin DeltaSelect may be available in the countries listed below.
Neostigmine metilsulfate (a derivative of Neostigmine) is reported as an ingredient of Neostigmin DeltaSelect in the following countries:
International Drug Name Search
Altosone may be available in the countries listed below.
Mometasone 17-(2-furoate) (a derivative of Mometasone) is reported as an ingredient of Altosone in the following countries:
International Drug Name Search
Drs. Foster and Smith CutStop styptic pads have been specially formulated as an aid in the control of minor bleeding. CutStop will also serve to temporarily relieve pain caused by clipping nails or small wounds.
Apply pad directly to bleeding area with slight pressure. If bleeding persists, or in the case of a puncture wound, consult a veterinarian immediately.
0.2% Benzocaine
Water, Ferric Subsulfate, Isopropyl Alcohol, Benzalkonium Chloride.
Item#1086
For questions or to reorder:
1-800-562-7169
www.DrsFosterSmith.com
Keep out of reach of children and pets to avoid unwanted consumption
Doctors Foster and Smith
CUTSTOP
Ready - to -Use
Styptic pads
Stops bleeding
from clipped nails
or small wounds
90 Pads
| DOCTORS FOSTER AND SMITH benzocaine liquid | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| unapproved drug other | 01/01/2001 | ||
| Labeler - Doctors Foster and Smith (122135148) |
| Registrant - United Pet Group (931135730) |
| Establishment | |||
| Name | Address | ID/FEI | Operations |
| JUNGLE LABORATORIES CORPORATION | 032615270 | manufacture | |
Polcrom may be available in the countries listed below.
Cromoglicic Acid disodium salt (a derivative of Cromoglicic Acid) is reported as an ingredient of Polcrom in the following countries:
International Drug Name Search
Generic Name: buprenorphine (transdermal) (BUE pre NOR feen)
Brand Names: Butrans
Buprenorphine is a narcotic (opioid) pain medicine.
Buprenorphine transdermal (skin patch) is used to treat moderate to severe chronic pain when treatment is needed around the clock.
Buprenorphine transdermal may also be used for purposes not listed in this medication guide.
Never wear more than 1 buprenorphine skin patch at a time unless your doctor has told you to.
Call your doctor at once if you have weak or shallow breathing, snoring that is new or unusual, slow heart rate, confusion, severe dizziness, seizure, or feeling like you might pass out.
asthma or severe breathing disorder; or
a bowel obstruction called paralytic ileus.
To make sure you can safely use buprenorphine, tell your doctor if you have any of these other conditions:
COPD (chronic obstructive pulmonary disease), sleep apnea, or other breathing disorders;
a personal or family history of "Long QT syndrome":
hepatitis B or C;
liver or kidney disease;
a thyroid disorder;
gallbladder disease;
curvature of the spine;
a history of head injury or brain tumor;
epilepsy or other seizure disorder;
low blood pressure;
Addison's disease or other adrenal gland disorders;
enlarged prostate, urination problems;
depression or other mental illness; or
a history of drug or alcohol addiction.
Your dose needs may be different if you have recently used an opioid pain medicine and your body is tolerant to it. Opioids include Tylenol #3, Lortab, Vicodin, OxyContin, Percocet, Darvocet, Actiq, morphine, and many others. Talk with your doctor if you are not sure you are opioid-tolerant.
Use exactly as prescribed. Never use buprenorphine in larger amounts, or for longer than recommended by your doctor. Follow the directions on your prescription label. Tell your doctor if the medicine seems to stop working as well in relieving your pain.
This medication comes with patient instructions for safe and effective use. Follow these directions carefully. Ask your doctor or pharmacist if you have any questions.
If you are switching to buprenorphine transdermal from another narcotic pain medicine, you may need to slowly stop using the other medicine. Follow your doctor's instructions.
Apply the skin patch only to clean, dry skin. Use only clear water to wash the skin before you apply a skin patch. Soaps or other chemicals could increase the amount of buprenorphine your skin absorbs.
Apply the patch to a flat and hairless area of the chest, back, side, or outer side of your upper arm. Wear the patch around the clock for 7 days. Never wear more than 1 buprenorphine skin patch at a time unless your doctor has told you to.
Do not use a buprenorphine transdermal skin patch if it has been cut or damaged.
After removing a skin patch fold it in half, sticky side in, and flush the patch down the toilet or use the Patch-Disposal Unit provided with this medication. Apply a new patch to a different skin area on the chest, back, side, or upper arm. Do not use the same skin area twice in a row.
Keep track of how many skin patches have been used from each new package of this medicine. Buprenorphine is a drug of abuse and you should be aware if any person in the household is using this medicine improperly or without a prescription.
If you forget to change a patch on your scheduled day, remove the patch and apply a new one as soon as you remember. Do not wear extra patches to make up a missed dose.
Overdose symptoms may include extreme drowsiness, weak or limp feeling, weak pulse, cold and clammy skin, fainting, shallow breathing, snoring, or breathing that stops.
slow heart rate, weak or shallow breathing, deep sighs, snoring that is new or unusual;
confusion, severe dizziness, feeling like you might pass out;
blisters, swelling, or severe irritation where the patch was worn;
seizure (convulsions); or
nausea, upper stomach pain, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).
Less serious side effects may include:
headache;
vomiting, dry mouth, upset stomach, constipation;
mild dizziness or drowsiness; or
redness, itching, or mild skin rash where the patch was worn.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Usual Adult Dose for Opiate Dependence:
Initial dose: 8 mg sublingually on day 1.
Maintenance dose: Rapidly titrate to the recommended target dose of 16 mg/day. In clinical trials, patients received 8 mg on day 1 and 16 mg on day 2 and thereafter. Further dose adjustments may be made in 2 mg to 4 mg increments up to a level that suppresses opioid withdrawal symptoms and holds the patient in treatment. The usual daily range is 4 mg to 24 mg sublingually.
The tablets should be placed under the tongue at the same time and allowed to dissolve. If patients are taking more than 2 tablets per dose and cannot hold more than 2 under the tongue comfortably, they should use 2 tablets at a time, allowing them to dissolve completely before taking more tablets.
For patients taking heroin or short-acting opioids, the first dose should be administered at least 4 hours after the patient last used opioids or preferably when early withdrawal symptoms appear.
Withdrawal symptoms may occur during buprenorphine induction treatment of patients taking methadone or long-acting opioids, especially high opioid doses or when buprenorphine is administered shortly after the last opioid dose. The optimal time for the first dose has not been reported.
The optimal method of tapering to discontinuation has not been reported.
Usual Adult Dose for Pain:
IM or IV:
Initial: 0.3 mg slow IM or IV every 6 hours as needed. May repeat once 30 to 60 minutes after the initial dose. Maximum single dose: 0.6 mg (IM only)
Transdermal patches: Apply 1 patch to a hairless or nearly hairless intact skin site. There are 8 possible application sites: upper outer arm, upper chest, upper back, and side of the chest (on both sides of the body). The patch is worn for 7 days. Maximum dose: 20 mcg/hour
Usual Pediatric Dose for Pain:
Less than 2 years: Safety and effectiveness have not been established.
2 to 12 years: 2 to 6 mcg/kg IM or slow IV every 4 to 6 hours.
13 to 18 years: 0.3 mg IM or slow IV every 6 hours; may repeat dose in 30 to 60 minutes.
dexamethasone (Decadron, Hexadrol);
St. John's wort;
rifabutin (Mycobutin), rifampin (Rifadin, Rifater, Rifamate), or rifapentine (Priftin);
phenobarbital (Solfoton) or other barbiturates;
diazepam (Valium) or similar medicines such as alprazolam (Xanax), lorazepam (Ativan), clorazepate (Tranxene), and others;
a heart rhythm medication such as amiodarone (Cordarone, Pacerone), disopyramide (Norpace), dofetilide (Tikosyn), flecaininde (Tambocor), procainamide (Pronestyl), propafenone, (Rythmol), quinidine (Quin-G), sotalol (Betapace), and others;
HIV medication such as efavirenz (Sustiva), etravirine (Intelence), nevirapine (Viramune), or ritonavir (Kaletra, Norvir); or
seizure medication such as carbamazepine (Carbatrol, Tegretol), felbamate (Felbatol), oxcarbazepine (Trileptal), phenytoin (Dilantin), or primidone (Mysoline).
This list is not complete and other drugs may interact with buprenorphine. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
See also: buprenorphine side effects (in more detail)
